Elezanumab + Placebo
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Ischemic Stroke
Conditions
Acute Ischemic Stroke
Trial Timeline
Nov 9, 2020 → Dec 23, 2024
NCT ID
NCT04309474About Elezanumab + Placebo
Elezanumab + Placebo is a phase 2 stage product being developed by AbbVie for Acute Ischemic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT04309474. Target conditions include Acute Ischemic Stroke.
What happened to similar drugs?
20 of 20 similar drugs in Acute Ischemic Stroke were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04309474 | Phase 2 | Completed |
| NCT04295538 | Phase 2 | Completed |
| NCT03737812 | Phase 2 | Completed |
| NCT03737851 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Ischemic Stroke